Squarepoint Ops LLC Purchases 753,060 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Squarepoint Ops LLC raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 113.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,417,152 shares of the biopharmaceutical company's stock after buying an additional 753,060 shares during the period. Squarepoint Ops LLC owned about 0.47% of Amicus Therapeutics worth $13,350,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in FOLD. Covestor Ltd boosted its position in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares in the last quarter. R Squared Ltd bought a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $79,000. KBC Group NV boosted its position in shares of Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 3,120 shares in the last quarter. Sciencast Management LP bought a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $100,000. Finally, Stephens Inc. AR bought a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $101,000.

Analysts Set New Price Targets

FOLD has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. UBS Group upped their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. The Goldman Sachs Group dropped their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, Wells Fargo & Company dropped their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Stock Performance

Shares of FOLD stock traded up $0.04 during trading on Wednesday, hitting $6.28. The company's stock had a trading volume of 769,326 shares, compared to its average volume of 3,345,774. The company has a market cap of $1.93 billion, a PE ratio of -34.86, a P/E/G ratio of 1.51 and a beta of 0.64. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The business has a fifty day moving average of $6.99 and a 200-day moving average of $8.66. Amicus Therapeutics, Inc. has a 52 week low of $5.81 and a 52 week high of $12.65.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.